EP1802277B1 - COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION - Google Patents

COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION Download PDF

Info

Publication number
EP1802277B1
EP1802277B1 EP05802312A EP05802312A EP1802277B1 EP 1802277 B1 EP1802277 B1 EP 1802277B1 EP 05802312 A EP05802312 A EP 05802312A EP 05802312 A EP05802312 A EP 05802312A EP 1802277 B1 EP1802277 B1 EP 1802277B1
Authority
EP
European Patent Office
Prior art keywords
liposomes
active ingredient
composition according
aqueous medium
sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05802312A
Other languages
German (de)
English (en)
Other versions
EP1802277A1 (fr
Inventor
Andreas Wagner
Karola Vorauer-Uhl
Hermann Katinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Priority to SI200530965T priority Critical patent/SI1802277T1/sl
Priority to EP05802312A priority patent/EP1802277B1/fr
Priority to PL05802312T priority patent/PL1802277T3/pl
Publication of EP1802277A1 publication Critical patent/EP1802277A1/fr
Application granted granted Critical
Publication of EP1802277B1 publication Critical patent/EP1802277B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Definitions

  • the present invention relates to pharmaceutical compositions based on topically administrable active substances in liposomes, which enhance the perfusion of tissues, in particular in the genital area, as well as the preparation of such compositions and their use.
  • Liposomes are known as controlled release pharmaceutical agents (see eg Overview by Ulrich, Biosci Rep. 2002; 22 (2): 129-50 ), or WO 96/14083 for SOD in liposomes.
  • the formulation of local anesthetics in topically applied liposomes is known in the art; z. B. describes US 4937078 Liposomes containing common sodium channel blockers such as tetracaine, lidocaine, etc.
  • chemical compounds are known which promote tissue perfusion and have become known, above all, through their use as a remedy for erectile disorders and impotence (see, for example, US Pat WO 94/28902 and EP 0967214 A1 ).
  • a liposomal composition based on lidocaine and a local anesthetic is disclosed for treatment Anorectal disorders can be used.
  • this composition may also contain sildenafil.
  • this object is achieved by providing a liposomal system for topical, in particular transdermal and / or transmucosal, administration of active substances which bring about smooth muscle relaxation, especially that of the feeding blood vessels in the genitals.
  • active substances which bring about smooth muscle relaxation, especially that of the feeding blood vessels in the genitals.
  • Such an effect may e.g. induced by an induced release of calcium ions.
  • the invention relates to a formulation in which the active ingredient, preferably from the group of prostaglandins, adenylate cytolases, cAMP, AMP, ATP, NO synthetases, nitric oxide (NO), NO compounds, nitrates, guanylate cyclases, cGMP, GMP, GTP and phosphodiesterases, in particular sildenafil, tadalafil and vardenafil, enclosed in liposomes and / or bound to liposomes.
  • the active ingredient preferably from the group of prostaglandins, adenylate cytolases, cAMP, AMP, ATP, NO synthetases, nitric oxide (NO), NO compounds, nitrates, guanylate cyclases, cGMP, GMP, GTP and phosphodiesterases, in particular sildenafil, tadalafil and vardenafil, enclosed in liposomes and
  • the inventive liposomal formulation is not only a temporary drug depot in the surrounding tissue, is released from the continuous substance, but also achieved a better bioavailability and longer half-life compared to the systemic application.
  • the relaxing effect on the smooth muscle cells leads to an increased circulation of the externally treated tissues, such as the genitalia, and consequently to an increased sensitivity and sensitivity in sexual activities.
  • Active substances or active substances in the context of the present invention are, in particular, those substances which intervene in the cAMP or cGMP circulation and cause an increased release of calcium ions.
  • these include, for example, substances such as papaverine, phentolamine, which stimulate the cAMP pathway; Nitric oxide (NO), which exerts an important transmitter function and activates a guanylate cyclase, which in turn cGMP forms; NO donors; Nitroglycerin; minoxidil, L-arginine; Linsidomine (produced in the body by NO synthetase by conversion of arginine to citrulline); molsidomine; Phosphodiesterase inhibitors, such as sildenafil or sildenafil citrate, which intervene in the cGMP pathway, with a PDE5 receptor involved; Prostaglandins such as alprostadil (PGE-1), dinoprostone (PGE-2), which interfere with the cAMP cycle.
  • PGE-1 alprosta
  • sildenafil As far as sildenafil is mentioned below, it also includes tadalafil, vardenafil and their acid salts, e.g. Sildenafil citrate and vardenafil-HCI 3H2O (vardenafil hydrochloride trihydrate), meaning, as far as does not result from the respective context of meaning otherwise.
  • a maximum loading density can be achieved by active loading of the liposomes with active ingredients. This process can be divided into two main categories: loading of the membrane and loading of the intraliposomal aqueous phase. Active substances containing protonatable groups, for example amino groups, can be enclosed in liposomes by H + gradient-controlled loading and then retained there in the protonated state. For this type of active loading, the most important feature is the liposome membrane / liposome medium partition coefficient. It was found that the octanol / buffer partition coefficient gives good indications provides for the transmembrane diffusion of a substance and is therefore relevant for the loading with active ingredient or for the release profile.
  • liposomes with different lipid composition preferably with long chain phospholipids and low cholesterol concentrations, were prepared in a suitable loading buffer, preferably in an ammonium sulfate or citric acid / sodium carbonate buffer.
  • a suitable loading buffer preferably in an ammonium sulfate or citric acid / sodium carbonate buffer.
  • the surrounding medium is modified, ie, exchanged or diluted, optionally neutralized or alkalized, thereby generating an H + gradient between the intraliposomal buffer and the extraliposomal medium.
  • the active substance migrates into the liposomes thanks to this H + gradient, where it is protonated and remains stable in the liposomes.
  • the extent of loading or loading capacity is determined primarily by the ratio of H + concentrations within and outside the liposomes.
  • active substance / lipid ratios in the range of 200-400 nmol of active ingredient per ⁇ mol of lipid to achieve similar values as are known from the literature on actively loaded liposomes.
  • An increase in the active ingredient concentration in the loading medium did not increase the loading capacity.
  • the active loading described above is a three-step process consisting of vesicle formation, drug addition and alkalization. It was therefore a further object of the invention to establish a one-step manufacturing process using the process described in U.S. Pat WO 02/36257 revealed cross-flow module could be realized.
  • a dilution buffer eg 5% glucose solution in the ammonium sulfate system or citric acid / sodium carbonate pH 9.0 - 9.5 in the citrate system.
  • the loading capacity can be further increased.
  • the efficiency of the process i. increase the amount of liposomal entrapped active ingredient per ml of suspension by increasing the lipid concentration either during production or during the subsequent filtration of the vesicles.
  • sildenafil When sildenafil is used as the active ingredient, the ammonium sulfate / glucose solution system is preferable for active loading since sildenafil is poorly soluble or not soluble in citrate buffer.
  • NH3 which is in a reversible equilibrium with ammonium sulfate in the intraliposomal aqueous medium, tends to migrate through the liposome membrane leaving an H + .
  • sildenafil migrates into the liposome, absorbing the hydrogen ion H + , making it more hydrophilic and thus remaining inside the membrane. In this way, sildenafil can be efficiently loaded into liposomes. This applies similarly to the sildenafil alternatives tadalafil and vardenafil.
  • lipids that can be used are, for example, phosphatidylethanotamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, cardiolipin, sphingomyelin, plasmalogens, glyceroglycolipids, ceramide, glycosphingolipids, neutral glycosphingolipids.
  • DPPC a phospholipid having an acyl chain length of 16 carbon atoms
  • DMPC 14 carbon chain length
  • a second way to reduce membrane rigidity and increase fluidity is to reduce the cholesterol level in the membrane.
  • DPPC DPPC
  • cholesterol 55:45 mol%
  • the amount of cholesterol was successively reduced to 38% and 30%, respectively, based on the total lipid content.
  • drug loading There was a slight decrease in drug loading compared to results with higher cholesterol levels.
  • these liposomes showed improved skin penetration properties and remained stable in the long-term test for weeks without significant loss of active ingredient.
  • cholesterol-free liposomes could be produced stably and successfully loaded with active substance, so that according to the invention the cholesterol content is in a range of 0-50 mol%, based on the total lipid content.
  • a third way to make liposomal membranes more flexible is to replace the fully saturated DPPC or DMPC lipids with chicken egg phosphatidylcholine (E-PC), a natural lipid mixture with unsaturated phospholipids.
  • E-PC chicken egg phosphatidylcholine
  • the liposomes are preferably mixed into a hydrogel which is easier to apply to the skin than a pure suspension.
  • it is within the scope of the present invention to prepare and apply topically other galenic formulations for the sildenafil liposomes in particular formulations in the form of solutions, lotions, emulsions, tinctures, sprays, ointments or creams.
  • Those skilled in the art are familiar with other options, as well as the pharmaceutically acceptable adjuncts and additives necessary to make the various galenic formulations.
  • Carbopol 981 NF Noveon
  • a hydrogel that can be used in very low concentrations, has proven useful in earlier experiments. It is approved for pharmaceutical use, relatively cheap to purchase and available in large quantities.
  • the liposomes are preferably prepared by the known crossflow method ( WO 02/36257 ) using an aqueous phase suitable for the desired active ingredient, wherein optionally at least a portion of the active ingredient is introduced into this aqueous phase and enclosed in the interior of the liposomes in the course of liposome formation.
  • an H + gradient between the inside and outside of the liposomes is generated, which transports both further protonatable drug from the dilution buffer quickly and efficiently in the liposomes also retains the active ingredient already included in the course of liposome formation.
  • a method can be selected in which buffer-filled liposomes are produced without active ingredient in a first step and the active substance is then loaded into the liposomes active only after the liposome production via an H + gradient, as described above.
  • the lipid mixture is dissolved in 96% ethanol and depending on lipid selection or lipid composition at a temperature in the range of 25 to 60 ° C, for example in the case of DPPC liposomes at a temperature of 50 to 55 ° C, with stirring.
  • the buffer solutions are preferably heated to the same temperature, for example 55 ° C.
  • the polar, aqueous phase (buffer) through the cross-flow module by means of a pump, e.g. a peristaltic pump is pumped, the ethanol / lipid solution is simultaneously injected under any preselectable pressure in the polar phase.
  • liposomes are preferably formed in the presence of an ammonium sulfate buffer (preferably 125 mmol).
  • an ammonium sulfate buffer preferably 125 mmol.
  • the aqueous phase remaining outside the liposomes in this case the ammonium sulfate solution, is modified, for example diluted with dilution buffer or replaced by diafiltration through a 5% glucose solution, whereby small amphiphilic molecules such as sildenafil can be loaded into the liposomes and protonated there in turn, NH3 escapes from the liposomes.
  • An aqueous 125 mM ammonium sulfate solution typically has a pH in the range of about 5-5.5.
  • sildenafil is not only taken up in the liposomes in one step, but also stably retained there.
  • the amount of sildenafil taken up in such a liposomal manner was also in a range from about 160 to 230 nmol of sildenafil per ⁇ mol of total lipids (DPPC + cholesterol), depending on the pH or H + gradient.
  • liposome-incorporated prostaglandin E1 was also prepared under similar process conditions. For application effects see example 2.
  • a formulation of 0.5 mg of the respective substance (calculated as salt-free active ingredient) in liposomes per 1 ml hydrogel Carbopol 981 NF was selected and by volunteers in an application amount of 0.5 - 1.5 ml used per application, where sildenafil and vardenafil were each used in the form of their acid salts (sildenafil citrate or vardenafil hydrochloride trihydrate).
  • the gel was applied by male volunteers by external application to the penis, by female subjects by external vaginal and / or clitoral application.
  • vaginal / clitoral application of the liposomal active ingredient gel begins the effect that causes increased blood flow, thereby a pleasant, warm feeling is created and as a result increased production of vaginal secretions has been noted.
  • the subjects reported slight contractions of the vaginal musculature (similar to orgasm), increased sexual sensation during intercourse, and a greater sense of orgasm.
  • the liposomal active substance preparations according to the invention in any case appear to be clearly effective in external use, even in women. They can therefore also be used for the therapeutic treatment of female sexual dysfunction (female sexual dysfunction, FSD), such as for the treatment of female sexual arousal disorder (FSAD).
  • FSD female sexual dysfunction
  • FSAD female sexual arousal disorder
  • prostaglandin E1 in liposomes For example, prostaglandin E1 in liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

  1. Composition pharmaceutique pour application topique, avec une principe actif, inclus dans des liposomes, exerçant, directement ou indirectement, un effet relaxant sur la musculature lisse, caractérisée en ce que les liposomes comprennent une proportion molaire de cholestérol dans la fourchette de 0 à 50 %, de préférence de 30 à 45 %, par rapport à la quantité globale de lipides, ainsi que, intérieurement, présentent un milieu aqueux ayant une valeur de pH dans la fourchette de 2,5 à 5,5 et, dans celui-ci, au moins un principe actif protoné, issu du groupe de la prostaglandine, des adénylatcyclases, cAMP, AMP, ATP, NO-synthétases, monoxyde d'azote (NO), combinaisons NO, nitrates, guanylate-cyclases, cGMP, GMP, GTP et phosphodiestérases, en une concentration d'au moins 100 nmoles par µmole de lipide, et où un milieu aqueux à valeur de pH neutre ou alcaline est présent à l'extérieur des liposomes.
  2. Composition selon la revendication 1, caractérisée en ce que, à l'intérieur des liposomes, est présent un milieu aqueux à valeur de pH dans la fourchette de 5,0 à 5,5 et, à l'extérieur des liposomes, est présent un milieu aqueux à valeur de pH dans la fourchette de 7 à 8.
  3. Composition selon la revendication 1 ou 2, caractérisée en ce que le principe actif est sélectionné dans le groupe des sildénafil, tadalafil et vardénafil, ainsi que leurs sels acides.
  4. Composition selon la revendication 3, caractérisée en ce que le principe actif est du sildénafil citrate et le milieu aqueux à l'intérieur des liposomes est un système tampon au sulfate d'ammonium.
  5. Composition selon l'une des revendications 1 à 4, caractérisée en ce que le milieu aqueux à l'intérieur des liposomes est un système tampon au sulfate d'ammonium et le milieu à l'extérieur des liposomes est une solution de glucose à 5 %.
  6. Composition selon l'une des revendications 1 à 3, caractérisée en ce que le milieu aqueux à l'intérieur des liposomes est un système tampon au citrate et le milieu à l'extérieur des liposomes est une tampon acide citrique/carbonate de sodium.
  7. Composition selon l'une des revendications 1 à 6, caractérisée en ce que les liposomes contiennent des phospholipides ayant une longueur de la chaîne acyl d'au moins 14, de préférence d'au moins 16, atomes de carbone.
  8. Composition selon l'une des revendications 1 à 7, caractérisée en ce que les liposomes présentent une taille moyenne dans la fourchette de 150 à 500 nm et contiennent le principe actif en une concentration dans la fourchette de 150 à 400 nmoles par µmole de lipide.
  9. Composition selon l'une des revendications 1 à 8, caractérisée en ce qu'elle se présente sous forme de suspension, lotion, émulsion, teinture, spray, gel, crème ou onguent, de préférence sous forme aseptique.
  10. Procédé de préparation d'une composition pharmaceutique définie aux revendications 1 à 19, caractérisé en ce que des liposomes spontanés, avec un milieu aqueux à l'intérieur de ceux-ci, sont produits par injection d'une phase lipide éthanolique ayant une proportion molaire de cholestérol de 0 à 50 %, de préférence de 30 à 45 %, rapportée à la quantité globale de lipide, dans une phase aqueuse ayant une valeur de pH dans la fourchette de 2,5 à 5,5, suite à quoi la phase aqueuse est modifiée, précisément diluée, soumise à échange, neutralisée ou alkalisée, de manière qu'un gradient H+ se constitue entre les côtés intérieur et extérieur des liposomes, et où un principe actif protonable, issu du groupe de la prostaglandine, des adénylatcyclases, cAMP, AMP, ATP, NO-synthétases, monoxyde d'azote (NO), combinaisons NO, nitrates, guanylate-cyclases, cGMP, GMP, GTP et phosphodiestérases,
    a) se présente dans la phase aqueuse et est absorbé au cours de la formation, s'effectuant spontanément, des liposomes, et/ou
    b) ensuite, une fois effectuée la formation de vésicules, est ajouté à la phase aqueuse modifiée et migre, le long du gradient H+, dans les liposomes,
    dont le resultat et la formation de liposomes qui contiennent le principe actif en une concentration d'au moins 100, en particulier dans la fourchette de 150 à 400 nmoles par µmole de lipide.
  11. Procédé selon la revendication 10, caractérisé en ce que la modification de la phase aqueuse est effectuée directement après avoir effectue la formation des liposomes, par dilution avec un tampon neutre ou alcalin, faisant qu'une valeur de pH de 7 à 8 est atteinte.
  12. Procédé selon la, revendication 11, caractérisé en ce que, avant la modification, la phase aqueuse présente une valeur de pH de 3,5 à 4,5 et contient du sulfate d'ammonium, et la modification est effectuée par dilution de la phase aqueuse avec une solution de glucose à 5 %.
  13. Procédé selon l'une des revendications 10 à 12, caractérisé en ce que la composition pharmaceutique est préparée sous forme de suspension, lotion, émulsion, teinture, spray, gel, crème ou onguent, de préférence sous forme aseptique.
  14. Composition pharmaceutique selon l'une des revendications 1 à 9, pour utilisation en tant que médicament, pour applications externes, en particulier topiques, transdermales et/ou par voie transmuqueuse, dans la zone génitale.
  15. Composition pharmaceutique selon la revendication 14, pour utilisation dans la prophylaxie et/ou la thérapie des troubles érectiles chez l'homme, dans le traitement des troubles sexuels de la femme, en particulier dans la thérapie des désordres de l'excitation féminine (FSAD, female sexual arousal disorder - désordre sexuel femelle d'éveil), ou pour l'augmentation de la sensation de plaisir sexuelle.
EP05802312A 2004-10-18 2005-10-14 COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION Active EP1802277B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200530965T SI1802277T1 (sl) 2004-10-18 2005-10-14 Liposomalni sestavek ki vsebuje učinkovino za relaksiranje gladke muskulature priprava tega sestavka in njegova terapevtska uporaba
EP05802312A EP1802277B1 (fr) 2004-10-18 2005-10-14 COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION
PL05802312T PL1802277T3 (pl) 2004-10-18 2005-10-14 Kompozycja liposomowa zawierająca aktywny składnik do rozluźniania mięśni gładkich, otrzymywania tej kompozycji i jej zastosowanie terapeutyczne

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04024753 2004-10-18
PCT/EP2005/011054 WO2006042701A1 (fr) 2004-10-18 2005-10-14 Composition liposomale contenant un principe actif destine a relaxer la musculature lisse, utilisation de cette composition et son utilisation therapeutique
EP05802312A EP1802277B1 (fr) 2004-10-18 2005-10-14 COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION

Publications (2)

Publication Number Publication Date
EP1802277A1 EP1802277A1 (fr) 2007-07-04
EP1802277B1 true EP1802277B1 (fr) 2010-01-13

Family

ID=35703778

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05802312A Active EP1802277B1 (fr) 2004-10-18 2005-10-14 COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION

Country Status (17)

Country Link
US (1) US8524274B2 (fr)
EP (1) EP1802277B1 (fr)
JP (1) JP5688199B2 (fr)
KR (1) KR101289917B1 (fr)
CN (1) CN101043874A (fr)
AT (1) ATE454884T1 (fr)
AU (1) AU2005296719B2 (fr)
CA (1) CA2583332C (fr)
DE (1) DE502005008880D1 (fr)
DK (1) DK1802277T3 (fr)
EA (1) EA011391B1 (fr)
ES (1) ES2339577T3 (fr)
NZ (1) NZ554183A (fr)
PL (1) PL1802277T3 (fr)
PT (1) PT1802277E (fr)
SI (1) SI1802277T1 (fr)
WO (1) WO2006042701A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
CN101269212B (zh) * 2008-04-30 2013-09-18 上海麟翔生物技术有限公司 一种可吞咽的漱口液
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
LT2523669T (lt) * 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
EP2556820A4 (fr) * 2010-04-05 2015-01-21 Sk Chemicals Co Ltd Composition contenant un inhibiteur de pde5 pour l'atténuation des rides de la peau
CO6280050A1 (es) * 2010-06-08 2011-05-20 Sante S A Lab Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa
RU2482847C2 (ru) * 2010-11-17 2013-05-27 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая силденафил или алпростадил, миноксидил или эуфиллин, тестостерон или йохимбин и липосомы для местного применения
WO2012094033A1 (fr) * 2011-01-05 2012-07-12 Livon Laboratories Procédés de fabrication de liposomes, compositions à base de liposomes préparées en utilisant les procédés, et procédés d'utilisation associés
EP2685962A1 (fr) 2011-03-17 2014-01-22 Transdermal Biotechnology, Inc. Systèmes topiques d'oxyde nitrique et leurs procédés d'utilisation
RU2618462C2 (ru) * 2011-12-26 2017-05-03 Тритек Биофармасьютикалз Ко., Лтд. Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
US9445993B2 (en) * 2012-04-16 2016-09-20 Rutgers, The State University Of New Jersey Nanotechnology approach for inhalation therapies
US8871257B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
EP3119420B1 (fr) * 2014-03-20 2021-09-22 Technion Research & Development Foundation Ltd. Système d'administration comprenant une enzyme protéolytique ou un effecteur associé destiné à être utilisé dans une méthode de traitement oral et utilisations associées
JP6744046B2 (ja) * 2015-03-16 2020-08-19 ミレカ メディシンズ ゲーエムベーハー ｃＧＭＰアナログの標的化されたリポソーム送達
US20190110988A1 (en) * 2017-10-17 2019-04-18 Lemulsa Technologies Inc. Delivery System That Utilizes Liposomal or Emulsion Vehicles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
FR2716110B1 (fr) * 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
WO1996014083A1 (fr) 1994-11-04 1996-05-17 Polymun Scientific Immunbiologische Forschung Gmbh Application de superoxide dismutase dans des liposomes
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2305394C (fr) 1997-10-28 2006-12-12 Vivus, Incorporated Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
RU2130771C1 (ru) * 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Способ получения липосомальных препаратов
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
IT1312310B1 (it) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
CA2408399A1 (fr) * 2000-05-09 2001-11-15 Nitromed, Inc. Thermographie infrarouge et procede d'utilisation d'applications associees
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1203614A1 (fr) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Procédé et dispositif pour la préparation de vésicules de lipides
US20060165766A1 (en) 2001-09-06 2006-07-27 Yechezkel Barenholz Method for preparing liposome formulations with a predefined release profile
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
AU2003245160B2 (en) * 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations

Also Published As

Publication number Publication date
DE502005008880D1 (de) 2010-03-04
EA200700892A1 (ru) 2007-08-31
KR101289917B1 (ko) 2013-07-25
CA2583332A1 (fr) 2006-04-27
PL1802277T3 (pl) 2010-07-30
SI1802277T1 (sl) 2010-05-31
US20090324698A1 (en) 2009-12-31
ATE454884T1 (de) 2010-01-15
AU2005296719B2 (en) 2011-02-03
JP2008516911A (ja) 2008-05-22
CA2583332C (fr) 2013-10-01
EP1802277A1 (fr) 2007-07-04
DK1802277T3 (da) 2010-05-17
KR20070069164A (ko) 2007-07-02
WO2006042701A1 (fr) 2006-04-27
PT1802277E (pt) 2010-04-01
NZ554183A (en) 2009-04-30
AU2005296719A1 (en) 2006-04-27
CN101043874A (zh) 2007-09-26
ES2339577T3 (es) 2010-05-21
JP5688199B2 (ja) 2015-03-25
EA011391B1 (ru) 2009-02-27
US8524274B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
EP1802277B1 (fr) COMPOSITION LIPOSOMALE CONTENANT UN PRINCIPE ACTIF DESTINE A RELAXER LA MUSCuLATURE LISSE ET L'EMPLOI THÉRAPEUTIQUE DE CETTE COMPOSITION
DE69935435T2 (de) Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
DE69735949T2 (de) Zusammensetzung geeignet zur behandlung der pferdelahmheit
DE60115045T2 (de) Verbesserte liposomale camptothecine und deren verwendungen
DE69512685T3 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
DE69837339T2 (de) Veränderung der Wirkstoffladung in multivesikulären Liposomen
DE69530368T2 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
DE69008729T2 (de) Verfahren zur herstellung einer öl-in-wasser-emulsion eines wirkstoffes.
DE60112102T2 (de) Kombination aus einem no-donor und einem antioxidans zur behandlung sexueller störungen
EP1737426A2 (fr) Inhibiteurs de la cholinesterase inclus dans des liposomes, leur production et leur utilisation
DE69425750T2 (de) Zweiphasige multilamellare lipidvesikel
DE69126703T2 (de) Zusammensetzung und verfahren zur behandlung von akne vulgaris und verzögerung des alterns
DE60123132T2 (de) Liposomenformulierung mit clobetasol propionate
KR20220154129A (ko) 항우울제 유발의 여성 성기능 장애 치료에서의 칸나비디올의 사용
JP6322575B2 (ja) 脂質マイクロカプセルのデリバリービヒクルを含む局所用製剤およびその使用
DE69804971T2 (de) Wässrige Biotinenthaltende Liposomenzusammensetzung
EP1392243A2 (fr) Composition topique lamellaire avec structure a membrane double contenant une n-acyl-ethanolamine et/ou un sel d'ammonium quaternaire et/ou une adenosylmethionine
CA2325930A1 (fr) Medicament pour prevenir et traiter la dysfonction sexuelle
WO2001005409A1 (fr) Nouvel anesthesiant pour anesthesie rachidienne et anesthesie peridurale
DE69212371T2 (de) Pharmazeutische Zusammensetzungen für die orale, kutane und intravaginale Anwendung in Form eines Schaums
DE3912685A1 (de) Pharazeutische praeparation, enthaltend felbinac
WO1995001776A1 (fr) Composition phospholipidique et utilisation de cette composition
MXPA00011386A (en) A medicament for prevention and treatment of sexual dysfunction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20081103

RTI1 Title (correction)

Free format text: LIPOSOMAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT FOR RELAXING SMOOTH MUSCLES AND THERAPEUTIC USE OF SAID COMPOSITION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 502005008880

Country of ref document: DE

Date of ref document: 20100304

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100326

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOGENSBERGER PATENT- & MARKENBUERO DR. BURKHARD BO

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100400847

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2339577

Country of ref document: ES

Kind code of ref document: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100113

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 7044

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100513

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E007791

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100113

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100113

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100413

26N No opposition filed

Effective date: 20101014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: FALLSGASSE 7, 9492 ESCHEN (LI)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 502005008880

Country of ref document: DE

Representative=s name: WUNDERLICH & HEIM PATENTANWAELTE PARTNERSCHAFT, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20210924

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20210924

Year of fee payment: 17

Ref country code: PL

Payment date: 20210924

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20210921

Year of fee payment: 17

Ref country code: NL

Payment date: 20211023

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20211023

Year of fee payment: 17

Ref country code: FI

Payment date: 20211027

Year of fee payment: 17

Ref country code: ES

Payment date: 20211103

Year of fee payment: 17

Ref country code: GB

Payment date: 20211023

Year of fee payment: 17

Ref country code: IE

Payment date: 20211021

Year of fee payment: 17

Ref country code: LU

Payment date: 20211023

Year of fee payment: 17

Ref country code: AT

Payment date: 20211027

Year of fee payment: 17

Ref country code: DE

Payment date: 20211027

Year of fee payment: 17

Ref country code: SE

Payment date: 20211023

Year of fee payment: 17

Ref country code: TR

Payment date: 20211012

Year of fee payment: 17

Ref country code: RO

Payment date: 20211004

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20210924

Year of fee payment: 17

Ref country code: IT

Payment date: 20211029

Year of fee payment: 17

Ref country code: HU

Payment date: 20211004

Year of fee payment: 17

Ref country code: GR

Payment date: 20211027

Year of fee payment: 17

Ref country code: FR

Payment date: 20211023

Year of fee payment: 17

Ref country code: CH

Payment date: 20211023

Year of fee payment: 17

Ref country code: BE

Payment date: 20211023

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502005008880

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20221031

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 7044

Country of ref document: SK

Effective date: 20221014

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 454884

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221014

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230414

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221101

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221015

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230503

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20230629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221015

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221015

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014